Despite the robust drug market for immune and infl ammatory diseases and their high prevalence, diagnostics associated
with these diseases do not constitute a large marketplace. Although researchers are working to discover
biomarkers, associate genes with disease, and develop diagnostics, a healthy commercial market for diagnostic
technologies and biomarker-based products in immune and infl ammatory therapeutic areas is still years away.
The present opportunity is to identify biomarkers with high levels of sensitivity and specificity that can be validated
for use in drug or diagnostic development and, particularly, in disease management to guide and target the
use of therapies.
Get the Answers You Need to Shape Your Strategy
Current ability to diagnose immune/infl ammatory diseases accurately and quickly is limited. What are the
common diagnostic approaches? Which indications exhibit the highest level of unmet need in terms of
diagnostics? How can diagnostics/biomarker developers tap the opportunities that current shortcomings
present?
Biomarkers do not currently play a large role in clinical practice, but their potential utility is apparent. What
do thought leaders say about biomarkers for immune/infl ammatory diseases? How can biomarkers
target and track therapies? What developments of note are under way?
Large companies are interested in using biomarkers or diagnostics developed by smaller companies to target
patients who are candidates for their immune/infl ammatory pipeline drugs. What proportion of the companies
involved in these deals are private/venture-backed companies, small-cap companies, or academic
institutions? How many of the 52 companies we analyze relied on backing from large-cap pharmaceutical
companies?
Diagnosis rates: diagnosed prevalence of select immune/infl ammatory diseases based on Decision
Resources’ epidemiology.
Current and future approaches: indication-specific modalities, challenges, opportunities, identified
and posited biomarkers, published research results.
Dealmaking: Select deals for diagnostics and biomarkers, indication focus of dealmaking, classifications
of dealmaking companies.
(0 items)
